Nivolumab & Hyaluronidase for Subcutaneous Administration: A Review of Efficacy and Safety Results from CheckMate 67T
Exploring a New Approach to Nivolumab Delivery
Join us for an in-depth review of Nivolumab and Hyaluronidase for Subcutaneous Administration—also known as OPDIVO Qvantig—an FDA-approved subcutaneous injection that offers a 3–5 minute alternative to traditional infusion.
Presented by Rehan Uddin, PharmD of Bristol Myers Squibb, this session will provide an overview of:
-
The role of OPDIVO Qvantig as a subcutaneous formulation of Nivolumab
-
Dosing and administration guidance
-
Efficacy and safety data
-
Key findings from the CheckMate 67T clinical trial
If you have any questions or would like to request the meeting invite, contact Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Related Content
Upcoming Webinar
BRAF V600E NSCLC: Updated Evidence for Encorafenib + Binimetinib
December 15, 2025 | 5:00 PM
December 16, 2025 | 2:00 PM